NASDAQ$SMLR

Semler Scientific Inc · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Semler Scientific's financial performance rebounded from the effects of the COVID-19 pandemic.

Semler Scientific reported financial results for the three and nine months ended September 30, 2020. The company's financial performance rebounded from the effects of the COVID-19 pandemic.

  • Financial performance rebounded from COVID-19 pandemic effects.
  • Continued profitability and generation of cash from operating activities expected.
  • Increased spending to support anticipated growth in business expected.
  • Actively trying to improve services and economics to the medical community.

Headline financials

Total Revenue

$10.7M

Previous: $8.9M+20.5%
EPS (adj)

$0.61

Previous: $0.96-36.5%
Capital Expenditures

$3K

Previous: $43K-93.0%
Free Cash Flow

$3.52M

Previous: $4.67M-24.7%
Net Income

$4.87M

Previous: $7.78M-37.4%
Operating Income

$5.56M

Previous: $3.11M+78.6%
Gross Profit

$9.91M

Previous: $7.93M+25.0%
Cash & Equivalents

$16.8M

Previous: $8.54M+96.6%
Total Assets

$28M

Previous: $18.9M+48.7%
Stock-Based Comp

$62K

Previous: $86K-27.9%

Revenue & EPS history

Semler Scientific · Revenue · Quarterly

$10.7M

Q3 2020+20.5%vs Q3 2019
Beat estimate in 11 of 13 quarters(85%)
ActualEstimate

Forward guidance

Semler Scientific expects continued profitability and generation of cash from operating activities, as well as increased spending to support anticipated growth in its business for the remainder of 2020 and in 2021. It is the company’s intent to grow revenues at a faster rate than expenses and to remain profitable. However, there remains some uncertainty as to state and local governments continuing to revise restrictions related to COVID-19.

Tailwinds

  • Continued profitability expected.
  • Generation of cash from operating activities expected.
  • Increased spending to support anticipated growth in business expected.
  • Intent to grow revenues at a faster rate than expenses.
  • Intent to remain profitable.

Headwinds

  • Uncertainty as to state and local governments continuing to revise restrictions related to COVID-19.
  • Semler Scientific intends to manage its expenses and other costs in line with changes in revenues and cash position during these uncertain times.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 6 quarterly earnings reports

Historical avg

-0.2%

Avg return

Earnings day

-2.4%

Avg return

5 days after

-5.8%

Avg return

30 days after

54%

25 / 46 earnings

Positive

+33.6%

Q4 2014

Best reaction

-33.3%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025-10.7%-16.0%-25.1%
Q2 2025-1.8%+2.0%-20.7%
Q1 2025-11.4%+17.9%-19.3%
Q4 2024+3.0%-12.4%-22.7%
Q3 2024+27.1%+29.9%+106.6%
Q2 2024-5.4%-1.7%-16.7%
Q4 2023-32.7%-36.8%-42.5%
Q3 2023+7.6%
Q2 2023+7.9%
Q1 2023+13.8%
Q4 2022+26.9%
Q3 2022-33.3%
Q2 2022+19.4%
Q1 2022-20.6%
Q4 2021-27.3%
Q3 2021-25.6%
Q2 2021-2.7%
Q1 2021+1.5%
Q4 2020+13.6%
Q3 2020+10.0%
Q2 2020-3.6%
Q1 2020-2.6%
Q4 2019+1.8%
Q3 2019+1.7%
Q2 2019+1.5%
Q1 2019-2.7%
Q4 2018+4.8%
Q3 2018-12.5%
Q2 2018+20.6%
Q1 2018+6.4%
Q4 2017+2.5%
Q3 2017+16.0%
Q2 2017-5.9%
Q1 2017+1.5%
Q4 2016+7.9%
Q3 2016-16.0%
Q2 2016+8.1%
Q1 2016-9.2%
Q4 2015-7.9%
Q3 2015+0.1%
Q2 2015-12.2%
Q1 2013+0.9%
Q4 2014+33.6%
Q3 2014-3.7%
Q2 2014-2.0%
Q1 2014+1.2%
Q4 2013
Q3 2013
Q2 2013
Q4 2012
Q3 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro